CanSino Biologics
CanSino Biologics (CanSinoBIO) is a bio pharmaceutical company primarily producing vaccines.
All edits
' fill='white' fill-rule='nonzero'%3e%3cpath d='M52 12c-22.048 0-40 17.952-40 40 0 10.848 4.48 21.376 12.288 28.864 7.008 6.752 16.096 10.592 25.792 11.04.48.032.992.096 1.472.096H52c10.336 0 20.128-3.904 27.616-11.04C87.616 73.312 92 63.04 92 52c0-22.048-17.952-40-40-40zm26.912 65.056c-1.472-5.216-8.448-8.032-13.696-10.112l-1.792-.736C60 64.8 60 63.488 60 61.6c0-1.344.672-3.264 1.888-4.416 3.104-2.72 4.736-6.464 4.736-10.816 0-8.8-6.144-15.168-14.624-15.168-8.448 0-14.336 6.24-14.336 15.168 0 4.544 1.536 8.192 4.512 10.816 1.248 1.12 1.792 3.072 1.792 4.416 0 1.344 0 3.008-4.16 4.704-5.12 2.112-11.904 4.992-15.008 10.432C18.688 69.984 15.2 61.12 15.2 52c0-20.288 16.512-36.8 36.8-36.8 20.288 0 36.8 16.512 36.8 36.8 0 9.408-3.52 18.208-9.888 25.056z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
In April 2020, CanSino Biologics advanced its vaccine candidate candidate, Ad5-nCoV, into PhasePhase II trials (Chinese registration number: ChiCTR2000030906). CanSino Biologics (CanSinoBIO) is collaborating with the National Research Council of Canada (NRC) to advance bioprocessing and clinical development of vaccine candidate against COVID-19, Ad5-nCoV. Ad5-nCoV was co-developed by the Beijing Institute of Biotechnology (BIB) and CanSinoBIO. A genetically engineering replication-defective adenovirus type 5 vector was used to express the SARS-CoV-2 spike protein which is produced in HEK293 cell lines designed and developed at the NRC. As of May 12, 2020, the vaccine is subject to approval by Health Canada for a Clinical Trial Application being filed by CanSinoBIO. As a preparatory step the Government of Canada announced $44 million in funding to support upgrades to NRC facilities in Montreal to ensure readiness for Canadian bioprocessing of potential vaccine candidates.
Find more companies like CanSino Biologics
